Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Guggenheim

Guggenheim upgraded shares of Entrada Therapeutics (NASDAQ:TRDA) to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

TRDA has been the topic of a number of other reports. Roth Mkm set a $13.00 price objective on shares of Entrada Therapeutics in a research note on Thursday, November 6th. Oppenheimer assumed coverage on shares of Entrada Therapeutics in a research report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.50.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $10.88 on Wednesday. The business has a 50-day moving average of $10.80 and a 200-day moving average of $8.05. The company has a market capitalization of $415.83 million, a price-to-earnings ratio of -4.37 and a beta of -0.12. Entrada Therapeutics has a 1 year low of $4.93 and a 1 year high of $13.82.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 8,910 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $9.98, for a total value of $88,921.80. Following the transaction, the chief financial officer owned 110,026 shares in the company, valued at approximately $1,098,059.48. This represents a 7.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.11% of the company’s stock.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of TRDA. Marshall Wace LLP bought a new position in shares of Entrada Therapeutics in the 4th quarter worth $212,000. Jacobs Levy Equity Management Inc. raised its holdings in Entrada Therapeutics by 14.9% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 362,786 shares of the company’s stock worth $3,729,000 after buying an additional 46,976 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Entrada Therapeutics by 19.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 221,269 shares of the company’s stock valued at $2,275,000 after buying an additional 36,010 shares in the last quarter. State Street Corp grew its holdings in shares of Entrada Therapeutics by 2.0% during the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock valued at $5,230,000 after buying an additional 10,174 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Entrada Therapeutics during the fourth quarter worth about $260,000. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.